Englander Institute for Precision Medicine
Found 869 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2025
Rajendran S, Rehani E, Phu W, Zhan Q, Malmsten JE, Meseguer M, Miller KA, Rosenwaks Z, Elemento O, Zaninovic N et al..  2025.  A foundational model for in vitro fertilization trained on 18 million time-lapse images.. Nat Commun. 16(1):6235.
Claridge SE, Nath S, Baum A, Farias R, Cavallo J-A, Rizvi NM, De Boni L, Park E, Granados GLara, Hauesgen M et al..  2025.  Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.. Clin Transl Med. 15(2):e70078.
Umesh A, Cordogan S, Simpson SK, Bram JT, Jones RH, Schairer WW, Sboner A, Elemento O, Green DW, Fabricant PD.  2025.  Genetic Variants Related to TGF-β Signaling Pathway Modulate Risk of Meniscus Injury: A Multiancestry Genome-wide Association Study.. Clin Orthop Relat Res.
Suhre K, Chen Q, Halama A, Mendez K, Dahlin A, Stephan N, Thareja G, Sarwath H, Guturu H, Dwaraka VB et al..  2025.  A genome-wide association study of mass spectrometry proteomics using a nanoparticle enrichment platform.. Nat Genet.
Borea R, Reduzzi C.  2025.  The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.. J Liq Biopsy. 8:100293.
Petroni G, Galassi C, Gouin KH, Chen H-H, Buqué A, Bloy N, Yamazaki T, Sato A, Beltrán-Visiedo M, Campia G et al..  2025.  IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages.. Nat Cancer.
Ge J, Han S, Shi M, Harada M, Yu S, Zheng J, Prehn C, Adamski J, Kastenmüller G, Schlesinger S et al..  2025.  Integrative Metabolomics of Targeted and Non-Targeted Analyses in T2D Progression.. Diabetes Care.
Hissong E, Bhinder B, Kim J, Ohara K, Ravichandran H, Assaad MAl, Elsoukkary S, Shusterman M, Khan U, Eng KWha et al..  2025.  Integrative transcriptomic and single-cell protein characterization of colorectal carcinoma delineates distinct tumor immune microenvironments associated with overall survival.. Pathol Res Pract. 273:156150.
Mizuno K, Ku S-Y, Venkadakrishnan VBalaji, Bakht MK, Sigouros M, Chan J, Trigos A, Driskill JH, Manohar J, King A et al..  2025.  Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.. Nat Commun. 16(1):5543.
Barton BM, Son F, Verma A, Bal SKumar, Tang Q, Wang R, Umphred-Wilson K, Khan R, Trichka J, Dong H et al..  2025.  IRE1α-XBP1 safeguards hematopoietic stem and progenitor cells by restricting pro-leukemogenic gene programs.. Nat Immunol.
Rowdo FPMadorsky, Martini R, Ackermann SE, Tang CP, Tranquille M, Irizarry A, Us I, Alawa O, Moyer JE, Sigouros M et al..  2025.  Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.. Cancer Res. 85(3):551-566.
Schiavone MLuisa, Scarpitta R, Ravera F, Bleve S, Reduzzi C, Di Cocco F, Dameri M, Zoppoli G, Naccarato AGiuseppe, Nuzzo PVitale et al..  2025.  Liquid biopsy in breast cancer: Redefining precision medicine.. J Liq Biopsy. 9:100312.
He Y, Waltman P, Kane T, Sigouros M, Chandra P, Gorski K, Zhang C, Proietti A, Singh A, Mittal V et al..  2025.  Longitudinal genomic analysis of five cases of recurrent thymomas.. J Thorac Oncol.
Howlader MJ, Rashighi M, Santambrogio L, Lu TT.  2025.  Lymphatic messengers: Non-antigen soluble mediators from diseased tissues to draining lymph nodes.. Curr Opin Immunol. 93:102536.
Albayram M, Richmond SB, Yagmurlu K, Tuna IS, Karakaya E, Ravichandran H, Tufan F, Lesha E, Mut M, Bunyak F et al..  2025.  Meningeal lymphatic architecture and drainage dynamics surrounding the human middle meningeal artery.. iScience. 28(11):113693.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Mesonephric Adenocarcinoma in a Young Male Patient.. Anticancer Res. 45(2):619-623.
Chen HJoyce, Gardner EE, Shah Y, Zhang K, Thakur A, Zhang C, Elemento O, Varmus H.  2025.  Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs.. Elife. 13
Srivastava N, Vomund AN, Yu R, Peterson OJ, Yang Y, Turicek DP, Abousaway O, Li T, Kain L, Stone P et al..  2025.  A microenvironment-driven HLA-II-associated insulin neoantigen elicits persistent memory T cell activation in diabetes.. Nat Immunol.
Ruan J, Bond DA, Shah BD, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D et al..  2025.  MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.. Blood Adv.
Tyrakis PA, Kampjut D, Steele GF, H Lindström JG, Chirnomas D, Hopkins BD, Goncalves MD, Mukherjee S, Cantley LC, Maddocks ODK.  2025.  Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.. Br J Cancer.
Kyei I, Bea VJ, Gyan KK, Adjei E, Stonaker B, Bekele M, Abebe E, Davis M, Boakye A, Boateng R et al..  2025.  Oncologic Anthropology and the African Diaspora: Twenty-Year Anniversary Report, International Center for the Study of Breast Cancer Subtypes (ICSBCS).. Ann Surg Oncol.
Bhinder B, Friedl V, Sethuraman S, Risso D, Chiotti KE, R Mashl J, Ellrott KP, Lee JA, Wong CK, Gyan K et al..  2025.  Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.. Sci Rep. 15(1):23921.
Panja S, Mantri P, Johnson KEnnu, Andrade-Martinez JSebastian, Yang S-R, Deshpande A, Tian H, Beg S, Ohara K, Leal A et al..  2025.  Passenger mutations link cellular origin and transcriptional identity in human lung adenocarcinomas.. Nat Genet.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. :102029.
K Devi SP, Wang E, Jaiswal A, Konieczny P, Kim T-G, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN et al..  2025.  PD-1 is requisite for skin TRM cell formation and specification by TGFβ.. Nat Immunol. 26(8):1339-1351.